The anticancer efficiency of the xenogeneic vaccine and the indication for its use

The anticancer efficiency of the xenogeneic vaccine and the indication for its use

Aim: To investigate the anticancer efficiency of the xenogeneic vaccine in different tumor models and to assess the possibility whe­ther level of antibodies (Ab) specific for vaccine’s proteins can be used as an indication for its use. Methods: Mice with Lewis lung carcinoma (LLC), Ehrlich carcinoma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental Oncology
Datum:2014
Hauptverfasser: Symchych, T.V., Fedosova, N.I., Karaman, O.M., Yevstratieva, L.M., Lisovenko, H.S., Voyeykova, I.M., Potebnia, H.P.
Format: Artikel
Sprache:English
Veröffentlicht: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2014
Schlagworte:
Original contributions
Online Zugang:https://nasplib.isofts.kiev.ua/handle/123456789/145335
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Zitieren:The anticancer efficiency of the xenogeneic vaccine and the indication for its use / T.V. Symchych, N.I. Fedosova, O.M. Karaman, L.M. Yevstratieva, H.S. Lisovenko, I.M. Voyeykova, H.P. Potebnia // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 79-84. — Бібліогр.: 33 назв. — англ.

Institution

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id nasplib_isofts_kiev_ua-123456789-145335
record_format dspace
spelling Symchych, T.V.
Fedosova, N.I.
Karaman, O.M.
Yevstratieva, L.M.
Lisovenko, H.S.
Voyeykova, I.M.
Potebnia, H.P.
2019-01-20T16:33:56Z
2019-01-20T16:33:56Z
2014
The anticancer efficiency of the xenogeneic vaccine and the indication for its use / T.V. Symchych, N.I. Fedosova, O.M. Karaman, L.M. Yevstratieva, H.S. Lisovenko, I.M. Voyeykova, H.P. Potebnia // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 79-84. — Бібліогр.: 33 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/145335
Aim: To investigate the anticancer efficiency of the xenogeneic vaccine in different tumor models and to assess the possibility whe­ther level of antibodies (Ab) specific for vaccine’s proteins can be used as an indication for its use. Methods: Mice with Lewis lung carcinoma (LLC), Ehrlich carcinoma (EC) or Sarcoma 37 (S37) were immunized with a xenogeneic anticancer vaccine based on chicken embryo proteins (CEP) and its anticancer activity was examined. The level of specific Ab in the blood serum of non-immunized tumor-bearing mice was studied by ELISA. Results: CEP application statically significantly inhibited the growth of LLC (the index of tumor growth inhibition was 42.10–53.13% depending on the day of tumor growth); vaccinated mice with EC showed significant tumor growth inhibition and life prolongation by 34.48%. Among mice with S37, there was noticed no antitumor effect. The number of tumor-bearing non-immunized mice which have had pre-existing CEP-specific Ab did not differ depending on the tumor model. The level of CEP-specific Ab among mice with LLC and EC increased with the growth of the tumor volume, but it decreased among mice be­aring S37. Probably, the low level of CEP-specific Ab alongside huge tumor burden shows it is futile to apply the CEP-based vaccine. Conclusion: Different tumor strains vary in their susceptibility to CEP-based vaccine. Probably, the low level of CEP-specific Ab when a tumor burden is huge shows it is futile to apply the CEP-based vaccine. Key Words: xenogeneic anticancer vaccine, chicken embryo proteins anticancer activity, Lewis lung carcinoma, Ehrlich carcinoma, Sarcoma 37, CEP-specific antibodies. Key Words: xenogeneic anticancer vaccine, chicken embryo proteins anticancer activity, Lewis lung carcinoma, Ehrlich carcinoma, Sarcoma 37, CEP-specific antibodies.
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Original contributions
The anticancer efficiency of the xenogeneic vaccine and the indication for its use
Article
published earlier
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
title The anticancer efficiency of the xenogeneic vaccine and the indication for its use
spellingShingle The anticancer efficiency of the xenogeneic vaccine and the indication for its use
Symchych, T.V.
Fedosova, N.I.
Karaman, O.M.
Yevstratieva, L.M.
Lisovenko, H.S.
Voyeykova, I.M.
Potebnia, H.P.
Original contributions
title_short The anticancer efficiency of the xenogeneic vaccine and the indication for its use
title_full The anticancer efficiency of the xenogeneic vaccine and the indication for its use
title_fullStr The anticancer efficiency of the xenogeneic vaccine and the indication for its use
title_full_unstemmed The anticancer efficiency of the xenogeneic vaccine and the indication for its use
title_sort anticancer efficiency of the xenogeneic vaccine and the indication for its use
author Symchych, T.V.
Fedosova, N.I.
Karaman, O.M.
Yevstratieva, L.M.
Lisovenko, H.S.
Voyeykova, I.M.
Potebnia, H.P.
author_facet Symchych, T.V.
Fedosova, N.I.
Karaman, O.M.
Yevstratieva, L.M.
Lisovenko, H.S.
Voyeykova, I.M.
Potebnia, H.P.
topic Original contributions
topic_facet Original contributions
publishDate 2014
language English
container_title Experimental Oncology
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
format Article
description Aim: To investigate the anticancer efficiency of the xenogeneic vaccine in different tumor models and to assess the possibility whe­ther level of antibodies (Ab) specific for vaccine’s proteins can be used as an indication for its use. Methods: Mice with Lewis lung carcinoma (LLC), Ehrlich carcinoma (EC) or Sarcoma 37 (S37) were immunized with a xenogeneic anticancer vaccine based on chicken embryo proteins (CEP) and its anticancer activity was examined. The level of specific Ab in the blood serum of non-immunized tumor-bearing mice was studied by ELISA. Results: CEP application statically significantly inhibited the growth of LLC (the index of tumor growth inhibition was 42.10–53.13% depending on the day of tumor growth); vaccinated mice with EC showed significant tumor growth inhibition and life prolongation by 34.48%. Among mice with S37, there was noticed no antitumor effect. The number of tumor-bearing non-immunized mice which have had pre-existing CEP-specific Ab did not differ depending on the tumor model. The level of CEP-specific Ab among mice with LLC and EC increased with the growth of the tumor volume, but it decreased among mice be­aring S37. Probably, the low level of CEP-specific Ab alongside huge tumor burden shows it is futile to apply the CEP-based vaccine. Conclusion: Different tumor strains vary in their susceptibility to CEP-based vaccine. Probably, the low level of CEP-specific Ab when a tumor burden is huge shows it is futile to apply the CEP-based vaccine. Key Words: xenogeneic anticancer vaccine, chicken embryo proteins anticancer activity, Lewis lung carcinoma, Ehrlich carcinoma, Sarcoma 37, CEP-specific antibodies. Key Words: xenogeneic anticancer vaccine, chicken embryo proteins anticancer activity, Lewis lung carcinoma, Ehrlich carcinoma, Sarcoma 37, CEP-specific antibodies.
issn 1812-9269
url https://nasplib.isofts.kiev.ua/handle/123456789/145335
citation_txt The anticancer efficiency of the xenogeneic vaccine and the indication for its use / T.V. Symchych, N.I. Fedosova, O.M. Karaman, L.M. Yevstratieva, H.S. Lisovenko, I.M. Voyeykova, H.P. Potebnia // Experimental Oncology. — 2014. — Т. 36, № 2. — С. 79-84. — Бібліогр.: 33 назв. — англ.
work_keys_str_mv AT symchychtv theanticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse
AT fedosovani theanticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse
AT karamanom theanticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse
AT yevstratievalm theanticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse
AT lisovenkohs theanticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse
AT voyeykovaim theanticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse
AT potebniahp theanticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse
AT symchychtv anticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse
AT fedosovani anticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse
AT karamanom anticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse
AT yevstratievalm anticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse
AT lisovenkohs anticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse
AT voyeykovaim anticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse
AT potebniahp anticancerefficiencyofthexenogeneicvaccineandtheindicationforitsuse
first_indexed 2025-12-07T15:12:54Z
last_indexed 2025-12-07T15:12:54Z
_version_ 1850862861677494273

Ähnliche Einträge